StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) company profile

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.38−0.03 (-6.28%)

Close on Nov 17, 2026Market cap $7.47MP/E –Yield –

About Ensysce Biosciences

Pharmaceutical Preparations, SIC 2834

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing proprietary drug platforms intended to prevent prescription drug abuse and overdose. Its technology includes Trypsin-Activated Abuse Protection (TAAP) and Multi-Programmed Abuse Resistance (MPAR), with lead opioid product candidates such as PF614 and PF614-MPAR designed for the management of severe to moderate chronic pain and the treatment of opioid use disorder. The company primarily targets patients requiring continuous analgesic therapy and healthcare markets affected by opioid misuse.

The company conducts its business within the United States, operating as a clinical-stage research and development enterprise that relies on third-party contract research and contract manufacturing organizations. Ensysce Biosciences maintains its principal executive offices in La Jolla, California.

Summary of the business section of Ensysce Biosciences's latest annual report, written by StockData.

Company profile

Company

Legal name
Ensysce Biosciences, Inc.
Founded
2003
Headquarters
La Jolla, CA
Address
7946 Ivanhoe Avenue, Suite 201 92037
Phone
(858) 263-4196
Employees
8, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Baker Tilly US, LLP, San Diego, California

Stock & identifiers

Ticker
ENSC
Former tickers
LACQ until Jul 1, 2021
Exchange
Nasdaq
IPO date
Dec 1, 2017
Shares outstanding
19M, Aug 12, 2026
Public float
$5.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-15 reverse, Dec 6, 2024; 1-for-12 reverse, Mar 31, 2023; 1-for-20 reverse, Oct 28, 2022; 9-for-4, Aug 16, 2021
SEC CIK
1716947
CUSIP
293602504
ISIN
US2936025046
FIGI
BBG00JFF4174
Share class FIGI
BBG00JFF4183
EIN
82-2755287

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
James William MorrisonPresident, Director–
Bob G. GowerDirector916,740

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2024$442.39K$442.39K$357.45K$0–
FY2023$508.58K$507.19K$417.15K$0–
FY2022$622.61K$152.79K$573.79K$1–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryOtherTotalvs. prior year
Dr. Lynn Kirkpatrick, PhD.
Chief Executive Officer
$432.04K$10.35K$442.39K-13%
Dave Humphrey
Chief Financial Officer
$360.92K$10.35K$371.27K-16%
Geoff Birkett
Chief Commercial Officer
$333.63K$10.01K$343.63K-12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Dec 1, 2017
Offer price
$10.00
Securities offered
20,000,000
Gross proceeds
$200.00M
Exchange
Nasdaq
First trading day
Dec 28, 2017
First-day close
$9.65-3.5%
Lock-up ends (est.)
Jun 26, 2018

“Each unit has an offering price of $10.00 and consists of one share of our common stock and one-half of one warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We have eight full-time employees and two part-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 6, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 22, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 27, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 5, 2025Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 23, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 17, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 10, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 31, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 16, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 17, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 7, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 7, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 30, 2021Name changeName changed from Leisure Acquisition Corp. to Ensysce Biosciences, Inc.
Jun 1, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 17, 2021Late filingNotification of late filing
Mar 15, 2021MergerRegistration of securities for a merger or exchange offer (S-4)
Nov 30, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 1, 2017IPOInitial public offering priced (424B4 prospectus)
Nov 28, 2017ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?